Effective management of pulmonary aspergillosis invading the thoracic spine in a child with high risk ALL requiring allogeneic bone marrow transplantation

References

• Jantunen E, Anttila V-J, Ruutu T. Aspergillus infections in allogeneic stem cell transplant recipients: have we made any progress?. Bone Marrow Transplant 2002; 30: 925–929
   PubMed Web of Science ®Google Scholar
• Jones BL, McLintock LA. Impact of diagnostic markers on early antifungal therapy. Curr Opin Infect Dis 2003; 16: 521–526
   PubMed Web of Science ®Google Scholar
• Kauffman CA. Clinical efficacy of new antifungal agents. Curr Opin Microbiol 2006; 9: 483–848
   PubMed Web of Science ®Google Scholar
• Johnson MD, Perfect JR. Combination antifungal therapy: what can and should we expect?. Bone Marrow Transplant 2007; 40: 297–306
   PubMed Web of Science ®Google Scholar
• Hagen EA, Stern H, Porter D, et al. High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin Infect Dis 2003; 36: 9–15
   PubMed Web of Science ®Google Scholar
• Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102: 827–833
   PubMed Web of Science ®Google Scholar
• Loeffler J, Hebart H, Sepe S, et al. Detection of PCR amplified fungal DNA by using a PCR-ELISA system. Med Mycol 1998; 36: 275–279
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45: 3487–3496
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005; 49: 4536–4545
   PubMed Web of Science ®Google Scholar
• Offner F, Cordonnier C, Ljungman P, et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998; 26: 1098–1103
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Maury S, Pautas C, et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell recipients. Bone Marrow Transplant 2004; 33: 943–948
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Finberg RW, Arndt C, et al. for the National Institute of Allergy and Infectious Diseases Mycoses Study Group. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764–771
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, et al. for the Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415
   PubMed Web of Science ®Google Scholar
• Maertens J, Raad I, Petrikkos G, et al. for the Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563–1571
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003; 187: 1834–1843
   PubMed Web of Science ®Google Scholar
• Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797–802
   PubMed Web of Science ®Google Scholar
• Liang DC. The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer. Paediatr Drugs 2003; 5: 673–684
   PubMedGoogle Scholar
• Mossad SB, Avery RK, Longworth DL, et al. Infectious complications within the first year after nonmyeloablative allogeneic blood stem cell transplantation. Bone Marrow Transplant 2001; 28: 491–495
   PubMed Web of Science ®Google Scholar
• Mielcarek M, Martin PJ, Leisenring W, et al. Graft versus-host disease after non- myeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756–762
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004; 48: 2166–2172
   PubMed Web of Science ®Google Scholar